Glial Activation and Expression of the Serotonin Transporter in Chronic Fatigue Syndrome.
Noda, Mami, Ifuku, Masataka, Hossain, Md Shamim et al. · Frontiers in psychiatry · 2018 · DOI
Quick Summary
This review examines how brain inflammation might cause ME/CFS symptoms. When the body fights off a viral infection, special immune cells in the brain called microglia and astrocytes can become overactive and trigger a chain of events that reduces serotonin levels—a chemical important for mood and energy. Understanding this pathway could help researchers develop new treatments for ME/CFS.
Why It Matters
This research provides a testable molecular framework for how infection or immune activation could trigger and maintain ME/CFS symptoms. Identifying specific pathways like serotonin dysregulation offers concrete targets for future drug development, potentially offering new treatment options for ME/CFS patients who currently lack effective therapies.
Observed Findings
Infection with viral mimetics triggers sequential activation of microglia and astrocytes in the brain
This immune activation leads to increased blood-brain barrier permeability
Astrocyte activation results in upregulation of the serotonin transporter (5-HTT)
Reduced serotonin availability decreases activation of the 5-HT1A receptor subtype
Inferred Conclusions
Neuroinflammation driven by microglia and astrocyte activation may be a central mechanism in immunologically-induced ME/CFS
Dysregulation of serotonin signaling through increased 5-HTT expression represents a plausible link between immune activation and ME/CFS symptoms
Therapeutic targeting of TLR3 signaling, IL-1β production, or serotonin transporter function may offer new treatment strategies for ME/CFS
Remaining Questions
Do these neuroinflammatory mechanisms actually occur in human ME/CFS patients, and can they be directly measured in clinical studies?
Which triggers (viral infections, other pathogens, non-infectious stressors) initiate this cascade in susceptible individuals?
What This Study Does Not Prove
This review does not provide direct human evidence that these mechanisms actually occur in ME/CFS patients—it synthesizes animal and cellular models. It does not prove that all cases of ME/CFS involve viral triggers or these specific immune pathways. The model describes association and proposed mechanisms, not definitive causation in human disease.
Are there genetic or immunological factors that determine whether an individual develops ME/CFS after immune activation?
Would therapeutic interventions targeting these pathways (e.g., TLR3 antagonists, IL-1β blockers, serotonin transporter modulators) be safe and effective in ME/CFS clinical trials?